MedTrace Logo

Integrated Cancer Repository for Cancer Research

NCT02012699 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 999999

Last updated 2026-05-05

No results posted yet for this study

Summary

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Conditions

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Kurt Fisher, MD, PhD · University of Nebraska

Eligibility

Min Age
19 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-01
Primary Completion
2099-12-31
Completion
2099-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02012699 on ClinicalTrials.gov